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Summary Glutathione content, enzyme activity and isoenzyme composition of glutathione S-transferases
were assayed in normal and Barrett's esophageal epithelium of ten patients with Barrett's esophagus. In
addition, gastric and duodenal specimens from the same patients were also investigated.
Glutathione content, glutathione S-transferase enzyme activity as well as glutathione S-transferase pi content
were all significantly lower in Barrett's epithelium as compared to normal esophageal mucosa. In contrast,
glutathione S-transferase class alpha enzymes are markedly expressed in Barrett's epithelium, whereas only low
amounts are present in normal esophageal epithelium. Glutathione and glutathione S-transferase composition
in Barrett's epithelium show striking similarities with gastric epithelium, whereas duodenal epithelium is
provided with considerable higher amounts of glutathione and glutathione S-transferases, except for levels of
glutathione S-transferase class pi, which are lower.
A significant negative correlation exists between glutathione S-transferase enzyme activity in the mucosa
along the gastrointestinal tract, and the tumour incidence. Since glutathione and glutathione S-transferase are
correlated with protection against cellular or cytogenetic damage, the low content of glutathione and
glutathione S-transferases in the Barrett's esophagus may be a factor of relevance for the increased tumour
risk in this tissue.
The normal esophagus is lined entirely by stratified
squamous epithelium. Barrett's esophagus is a condition
wherein squamous epithelium is replaced by columnar
epithelium. Replacement of the normal squamous epithelium
of the esophagus with Barrett's epithelium is considered a
premalignant condition for esophageal cancer. Patients with
Barrett's epithelium have a 30-40 times increased risk of
developing esophageal adenocarcinomas as compared to a
normal population (Spechler et al., 1984; Cameron et al.,
1985). Recently a 10% yearly rate of increase of adenocar-
cinoma of the esophagus and gastric cardia in males was
found, which exceeds that of any other cancers (Blot et al.,
1991).
Biotransformation enzymes, and in particular glutathione
S-transferases are present in most epithelial tissues of the
human gastrointestinal tract (Peters et al., 1991; Peters et al.,
1990b). Their function is protection of the tissue against toxic
or carcinogenic compounds, entering the body as food com-
ponents, food additives or drugs (Peters et al., 1991; Manner-
vik & Danielson, 1988; Koster et al., 1989). Such compounds
may be metabolised by conjugation with glutathione yielding
less harmful and more water soluble molecules, which are
then excreted via bile or urine. Cytosolic glutathione S-
transferases are a family of enzymes divided into three
classes, called alpha, pi and mu. Recently a fourth class
(theta) has been reported (Meyer et al., 1991). Complete
absence or reduced levels of class mu glutathione S-
transferases have been implicated in the increased risk of
lung carcinoma in smokers (Seidegard et al., 1990); however
these results are contradictory to the recent data of Zhong et
al. (1991). Similarly, glutathione S-transferase mu deficiency
has been claimed to increase the risk of developing stomach
or colon cancer (Strange et al., 1991), but our results are not
in agreement with this conclusion (Peters et al., 1990a; Peters
et al., 1990b; Peters et al., 1992). However, increased
cytogenetic damage was observed in studies with glutathione
S-transferase mu deficient human blood cells in vitro
(Wiencke et al., 1990; Van Poppel et al., 1992). Such studies
suggest that tissues with low or reduced levels of glutathione
and glutathione S-transferases may have a reduced capacity
to detoxify carcinogens, resulting in more cytogenetic
damage, which in turn could lead to a higher tumour
risk.
The purpose of our study was to investigate the
glutathione content and glutathione S-transferase enzyme
activity and isoenzyme levels in Barrett's esophagus, in rela-
tion to the surrounding normal epithelia.
Materials and methods
Tissue
Tissue samples were obtained during routine endoscopic
inspection of ten patients with Barrett's esophagus. Patient
data are given in Table I. Epithelial tissue (three biopsy
specimens at each location) was obtained from normal
esophagus epithelium, Barrett's esophagus, gastric cardia (six
patients), gastric antrum and duodenum. Biopsies were
frozen in liquid nitrogen immediately, and were stored at
-80°C until use.
Tissue was homogenised in a glass/glass potter after dilu-
tion with approximately six volumes of 20 mM Tris/HCI
buffer pH 7.4, containing 0.25 M sucrose and 1.4 mM dithio-
threitol. Cytosolic fractions were made by centrifugation at
150,000 g for 50 min.
The investigations were approved by the local ethical com-
mittee on human experimentation.
Assays
Protein was assayed by the method of Lowry et al. (1951).
Glutathione S-transferase enzyme activity with l-chloro 2,4-
dinitrobenzene as substrate, by the method of Habig et al.
(1974). Reduced glutathione was quantified by high perform-
ance liquid chromatography by the method of Fahey and
Newton (1987). The different classes of glutathione S-trans-
ferases were quantified in the cytosolic fractions after den-
sitometric analysis of immunoblots, essentially as described
recently (Peters et al., 1992). The coefficient of variation of
this method is 10-15%. Immunodetection was performed
with monoclonal antibodies against cytosolic class alpha,
class mu and class pi glutathione S-transferases. Class alpha
antibodies react against GST Al-i, GST A1-2 and GST A2-2
(Peters et al., 1992), class mu antibodies recognise GST
MIa-la, GST MIa-Ib and GST Mlb-lb (Peters et al., 1990a;
Van Ommen et al., 1990), and class pi antibodies are directed
against GST P1-I (Peters et al., 1989).
Statistics
The Wilcoxon signed rank test was used to assess statistical
differences between the various parameters investigated.
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Table I Patient data
Age
Patient Gender (yrs) Esophagus pathology' Medication
1 Female 53 Intestinal type; milddysplasia (10cm)b Omeprazole 2 x 20 mg
2 Male 55 Intestinal type;metaplasia (3 cm) Omeprazole 1 x 20mg
3 Male 67 Nodysplasia(7cm) Tagamet 1 x 800mg
4 Male 25 Nodysplasia(5 cm) None
5 Male 83 Intestinal type;metaplasia(9 cm) Omeprazole 1 x 20mg
6 Male 71 Intestinal type;metaplasia(7 cm) Zantac2 x 150mg
7 Male 45 Intestinal type;metaplasia, Omeprazole2 x 20mg
milddysplasia (4 cm) Cisapride4 x 10mg
8 Male 56 Moderatedysplasia(5 cm) Omeprazole 1 x 20mg
9 Male 59 Milddysplasia(3 cm) Omeprazole 1 x 20mg
10 Male 63 Nodysplasia(7 cm) Omeprazole I x 20mg
'Barrett'sepithelium in theloweresophaguswasconfinnedinallpatientsafterinvestigation of
biopsy specimens byapathologist. bLength ofBarrett's columnarepitheliumin cm.
Table II Glutathione and glutathione S-transferases in Barrett's epithelium and in normal
epithelium of the upper gastrointestinal tract
Glutathione Glutathione S-transferase content
Glutathione S-transferase (ngmg-I cytosolic protein)
(nmolmg' (nmolmin-' mg(s
Tissue protein protein) Class a Class p Class i
Esophagus 64 ± 9 482 ± 61 456 ± 268 518 ± 188 8511 ± 1606
epithelium (25-109) (215-840) (0-2689) (0-1653) (1254-13682)
Barrett's 27 ± 3a 334 ± 33' 2626 ± 528a 532 ± 204 5023 ± 1045a
epithelium (15-48) (186-467) (412-4843) (0-2062) (967-10403)
Gastric 20± 3 331 ± 26 2480± 1025 263 ± 169 3384± 859
cardia (12-29) (189-506) (1106-8439) (0-1130) (52-5723)
Gastric 23 ± 2 394 ± 49 2665 ± 581 611 ± 248 5101 ± 987
antrum (8-29) (204-634) (315-5732) (0-2508) (1458-9840)
Duodenum 34 ± 4b 599 ± 39b 6899 ± 776b 930 ± 320 2535 ± 483b
(18-54) (369-831) (4120-11546) (0-2810) (1207-6068)
Values are given as mean ± s.e.m.; range is indicated in parenthesis. 'Significantly different when
compared to normal esophageal epithelium (P <0.02). bSignificantly different when compared to
gastric antrum, gastric cardia or esophagus (P<0.05).
Results
As compared to normal esophageal epithelium, the content
of glutathione in Barrett's epithelium is significantly lower in
all patients investigated. Values are comparable to those of
gastric epithelium, whereas in the proximal small intestine
(duodenum) values are significantly higher again (Table II).
Individual values are higher in eight out ofnine patients, and
are given in Figure 1. In parallel, glutathione S-transferase
enzyme activity in Barrett's epithelium is lower as compared
to the normal esophageal epithelium in eight out of ten
patients, and is very similar to the levels in the gastric
mucosa. In duodenal mucosa glutathione S-transferase
activity is highest (Table II and Figure 1).
Glutathione S-transferase content of each class (alpha, mu
and pi) was quantified by immunodetection with monoclonal
antibodies on Western blots, followed by densitometric
analysis of the staining intensity using purified enzymes as
marker proteins. Results of glutathione S-transferase isoen-
zyme content obtained from patient 1 are shown in Figure 2.
All individual results are shown in Figure 1. Class alpha
glutathione S-transferase content is undetectable in four
patients and mean value is very low in normal esophagus
(Table II). In contrast, this class of enzymes is present in
considerable amounts in Barrett's epithelium, where the levels
are very similar to those in the stomach. Duodenal values are
highest (Table II).
Class mu glutathione S-transferases are present in six out
of ten patients. Values are very similar in normal and
diseased esophagus and stomach, and are highest in the
duodenum. Class pi glutathione S-transferase levels are
highest in normal esophageal epithelium and are significantly
lower in Barrett's epithelium and in the epithelium of
stomach and duodenum. In the gastric cardia, as compared
to the gastric antrum there is a tendency towards lower levels
of glutathione, glutathione S-transferase enzyme activity as
well as in the content of glutathione S-transferase isoforms,
but the differences in value are not statistically significant.
Data on human gastrointestinal glutathione S-transferase
enzyme activities presented in this study extended with earlier
data published by us (Peters et al., 1990b; 1991 and 1992) are
plotted semilogarithmically against the tumour incidence at
different sites of the gastrointestinal tract (Figure 3). A very
good correlation is found (r = 0.997).
Discussion
Drug metabolising enzymes such as glutathione S-trans-
ferases in the epithelium of the gastrointestinal tract repre-
sent a first line of defence against ingested xenobiotics arnd
carcinogens (Coles & Ketterer, 1990; Noordhoek & van
Bladeren, 1991). Glutathione is an important determinant of
protection against chemical injury, by serving as a substrate
for glutathione S-transferases, which catalyse the reaction of
glutathione with electrophilic compounds to form non toxic
conjugates (Siegers, 1989). In this respect it may be relevant
that low levels ofglutathione S-transferase enzyme activity or
absence of certain glutathione S-transferase isoforms are cor-
related with an increased risk for developing cytogenetic
damage, or even tumours. In addition, glutathione and other
sulfhydryl compounds may protect the gastrointestinal
mucosa against drug induced damage (Lash et al., 1986;
Hirota et al., 1989; Salim, 1990; Romano et al., 1992). Fur-
thermore, inhibition of glutathione synthesis in newborn rats
gives rise to more endogeneously produced oxidative stress
(Martensson et al., 1991).
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Figure 2 Immunodetection of glutathione S-transferase isoen-
zymes in esophageal, gastric and duodenal epithelium of a patient
with Barrett's esophagus. Cytosolic fractions (40gg protein) from
normal esophagus (o), Barrett's esophagus (b), gastric antrum (a)
and duodenum (d) of patient number I were subjected to SDS
polyacrylamide gel electrophoresis (10% acrylamide, w/v) and
subsequent Western blotting. Western blots were incubated with
monoclonal antibodies against glutathione S-transferase class
alpha (upper panel), class pi (middle panel) and class mu (lower
panel). Lane m contains purified class alpha, pi and mu
glutathione S-transferases, respectively.
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Figure 1 Glutathione and glutathione S-transferases in
esophageal, gastric and duodenal epithelia of patients with Bar-
rett's esophagus. Glutathione, glutathione S-transferase enzyme
activity and isoenzyme composition are determined in cytosolic
fractions as described under Materials and methods, and in the
legend of Figure 2.
enzyme activity and content of glutathione and glutathione
S-transferase pi are significantly lower as compared to the
normal esophageal epithelium. On the other hand glutathione
S-transferase alpha is expressed at higher levels in Barrett's vs
normal epithelium (mean ratio 5.75). Alpha and pi class
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Figure 3 Tumour incidence and glutathione S-transferase
enzyme activity in epithelia of the gastrointestinal tract. Mucosal
glutathione S-transferase activity in the different parts of the
gastrointestinal tract was plotted against the tumour incidence in
the Dutch population (CBS, 1987). Glutathione S-transferase
activities in the small intestine (n = 14) are obtained from Table
II and Peters et al. (1991). Values of esophagus (n = 10) are from
Table II, gastric values are from Table II and Peters et al.
(1990b), and data of colon/rectum (n = 24) are from Peters et al.
(1992). Values are given as means ± s.d.
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glutathione S-transferase enzymes have quite different sub-
strate specificities for various potentially harmful substances,
and one could argue that Barrett's tissue may have increased
protection due to the increased alpha class enzymes. However
the clinical data unambiguously show that the Barrett's
epithelium is more susceptible to carcinogenesis.
Glutathione content and glutathione S-transferase isoen-
zyme pattern in the Barrett's epithelia is very similar to those
found in gastric epithelia. This is remarkable since five out of
ten cases of the Barrett's epithelia investigated here are
classified histologically as intestinal type of tissue. This aspect
deserves to be reinvestigated in an immunohistochemical
study, using antibodies against the glutathione S-transferase
isoforms.
Plotting the tumour incidence at the different sites of the
gastrointestinal tract against the epithelial glutathione S-
transferase enzyme activity, it is striking that at sites where
glutathione S-transferase activity is lowest, tumour incidence
is highest (Figure 3). Such a trend seems to be present also
for other tissues, since glutathione S-transferase activity is
high in liver and kidney (Howie et al., 1990) where tumour
incidence is relatively low, at least in the livers from non-
hepatitis B infected individuals, whereas glutathione S-
transferase activity in lung and breast is low (Howie et al.,
1990), and here tumour incidence is high (CBS, 1987). One
has to realise however that at sites where glutathione
S-transferase activity is low, low expression levels of other
biotransformation enzymes may occur, as found for the
colon (Peters et al., 1991).
Assuming the plot of Figure 3 has some relevance for
carcinogenesis, the lower glutathione S-transferase enzyme
activity in Barrett's epithelium as compared to normal
esophageal epithelium (334 vs 482 nmol min- mg-' protein)
may correspond with a tumour incidence of 9.7 cases/100,000
population for patients with Barrett's esophagus. With an
estimated prevalence for Barrett's esophagus of 376 cases per
100,000 population (Cameron et al., 1990), this would mean
that approximately one out of 40 patients with Barrett's
esophagus would develop esophageal adenocarcinoma. This
number fits extremely well with data obtained from two
different studies, where two out of 104 (Cameron et al., 1985)
and two out of 105 (Spechler et al., 1984) patients with
Barrett's esophagus did develop esophageal adenocarcinomas
after a mean interval of 8.5 and 3.5 years, respectively.
In conclusion, glutathione content as well as glutathione
S-transferase enzyme activity are significantly lower in Bar-
rett's epithelium when compared to squamous esophageal
mucosa. This may contribute to the increased risk for
developing esophageal adenocarcinomas in these patients.
Modulation of glutathione and glutathione S-transferase
levels by supplementation with glutathione or its precursors,
or increasing the enzyme activity by inducers of glutathione
S-transferases may therefore be of value to prevent malignant
transformation of Barrett's epithelium.
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